Abstract:Background Intestinal fibrosis is a common complication of Crohn's disease (CD) and is characterized by the excessive accumulation of extracellular matrix produced by activated myofibroblasts. Caveolin-1 (CAV1) inhibits fibrosis. However, limited data show that CAV1 affects intestinal fibrosis. Methods Human CD tissue samples were gained from patients with CD who underwent surgical resection of the intestine and were defined as stenotic or nonstenotic areas. A dextran sodium sulfate-induced mouse model of intestinal fibrosis was established. For in vitro experiments, we purchased CCD-18Co intestinal fibrosis cells and isolated and cultured human primary colonic fibroblasts. These fibroblasts were activated by transforming growth factor beta administration for 48 hours. In the functional experiments, a specific small interfering RNA or overexpression plasmid was transfected into fibroblasts. The messenger RNA levels of fibrosis markers, such as alpha-smooth muscle actin, fibronectin, connective tissue growth factor, and collagen I1 alpha, were determined using quantitative polymerase chain reaction. Western blot analysis was applied to detect the expression of CAV1, SQSTM1/p62 (sequestosome 1), and other fibrosis markers. Results In human CD samples and the dextran sodium sulfate-induced mouse model of intestinal fibrosis, we observed a downregulation of CAV1 in fibrosis-activated areas. Mechanistically, CAV1 knockdown in both human primary colonic fibroblasts and CCD-18Co cells promoted fibroblast activation, while CAV1 overexpression inhibited fibroblast activation in vitro. We found that SQSTM1/p62 positively correlated with CAV1 expression levels in patients with CD and that it was indirectly modulated by CAV1 expression. Rescue experiments showed that CAV1 decreased primary human intestinal fibroblast activation by inhibiting fibroblast autophagy through the modulation of SQSTM1/p62. Conclusions Our data demonstrate that CAV1 deficiency induces fibroblast activation by indirectly regulating SQSTM1/p62 to promote fibroblast autophagy. CAV1 or SQSTM1/p62 may be potential therapeutic targets for intestinal fibrosis. Lay Summary Intestinal fibrosis is a common complication of Crohn's disease. In human Crohn's disease samples and a mouse model of intestinal fibrosis, we observed a downregulation of caveolin-1 (CAV1) in fibrosis-activated areas. Mechanistically, CAV1 deficiency induces fibroblast activation by indirectly regulating SQSTM1/p62 (sequestosome 1) to promote fibroblast autophagy. CAV1 or SQSTM1/p62 may be potential therapeutic targets for intestinal fibrosis.

CAV1 Prevents Gallbladder Cholesterol Crystallization by Regulating Biosynthesis and Transport of Bile Salts

Adeno-associated Virus-Based Caveolin-1 Delivery Via Different Routes for the Prevention of Cholesterol Gallstone Formation

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Expression and Its Significance of Caveolin–1 in Liver and Gallbladder of Gallstone Mice Model

Association of Caveolin-3 and Cholecystokinin A Receptor with Cholesterol Gallstone Disease in Mice

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

Differences Between Hepatic and Biliary Lipid Metabolism and Secretion in Genetically Gallstone-Susceptible and Gallstone-Resistant Mice

Activation of Constitutive Androstane Receptor Prevents Cholesterol Gallstone Formation

Caveolin1 Protects Against Diet Induced Hepatic Lipid Accumulation in Mice.

Cav‐1 regulates the bile salt export pump on the canalicular membrane of hepatocytes by PKCα‐associated signalling under cholesterol stimulation

Characteristics of Mrna Levels of Hepatic Cholesterol Metabolism Regulatory Enzymes in Genetically Gallstone-Susceptible and Resistant Mice

FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice

Hyodeoxycholic acid attenuates cholesterol gallstone formation via modulation of bile acid metabolism and gut microbiota

Caveolin-1 Alleviates Crohn's Disease-induced Intestinal Fibrosis by Inhibiting Fibroblasts Autophagy Through Modulating Sequestosome 1.

Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation

Role of Baicalin and Liver X Receptor Alpha in the Formation of Cholesterol Gallstones in Mice

Ursodeoxycholic Acid Protects Interstitial Cajal-like Cells in the Gallbladder from Undergoing Apoptosis by Inhibiting TNF-α Expression

Caveolin-1 Deficiency Protects Mice Against Carbon Tetrachloride-Induced Acute Liver Injury Through Regulating Polarization of Hepatic Macrophages

Upregulation of Caveolin-1 and SR-B1 in Mice with Non-Alcoholic Fatty Liver Disease

Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones

The mRNA expression of hepatic scavenger receptor B type I and liver receptor homologue 1 in Patients with cholesterol gallstone disease